Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity

EBioMedicine

Volumn 13, Issue , 2016, Pages 37-45

  Carlucci, Christian ^a   Petrof, Elaine O ^b   Allen Vercoe, Emma ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Dysbiosis; Fecal; Gut; Microbiome; Therapeutic; Transplant

Indexed keywords

METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

BODY MASS; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG SAFETY; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; FOOD AND DRUG ADMINISTRATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; MICROBIAL DIVERSITY; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULCERATIVE COLITIS; ANIMAL; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; TREATMENT OUTCOME;

ANIMALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; OBESITY; RECURRENCE; TREATMENT OUTCOME;

EID: 84992013403     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.09.029     Document Type: Review

References (103)

1. Abt, M.C., McKenney, P.T., Pamer, E.G., Clostridium difficile colitis: pathogenesis and host defence. Nat. Rev. Microbiol. 10 (2016), 609–620.
2. Advancing Bio, https://http://www.advancingbio.org, 2016.
3. Agrawal, M., Aroniadis, O.C., Brandt, L.J., Kelly, C., Freeman, S., Surawicz, C., Broussard, E., Stollman, N., Giovanelli, A., Smith, B., Yen, E., Trivedi, A., Hubble, L., Kao, D., Borody, T., Finlayson, S., Ray, A., Smith, R., The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J. Clin. Gastroenterol. 5 (2016), 403–407.
4. American Gastroenterological Association (AGA), AGA establishes NIH-funded registry to track fecal microbiota transplants. http://www.gastro.org/press_releases/aga-establishes-nih-funded-registry-to-track-fecal-microbiota-transplants, 2016.
5. Antharam, V.C., Li, E.C., Ishmael, A., Sharma, A., Mai, V., Rand, K.H., Wang, G.P., Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 9 (2013), 2884–2892.
6. Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., Kim, S., Fritz, J.V., Wilmes, P., Ueha, S., Matsushima, K., Ohno, H., Olle, B., Sakaguchi, S., Taniguchi, T., Morita, H., Hattori, M., Honda, K., Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 7461 (2013), 232–236.
7. Boulange, C.L., Neves, A.L., Chilloux, J., Nicholson, J.K., Dumas, M.E., Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome. Med., 1, 2016, 42.
8. Bouma, G., Strober, W., The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 7 (2003), 521–533.
9. Burton, J.H., Johnson, M., Johnson, J., Hsia, D.S., Greenway, F.L., Heiman, M.L., Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J. Diabetes Sci. Technol. 4 (2015), 808–814.
10. Chang, J.Y., Antonopoulos, D.A., Kalra, A., Tonelli, A., Khalife, W.T., Schmidt, T.M., Young, V.B., Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 3 (2008), 435–438.
11. Cornely, O.A., Miller, M.A., Louie, T.J., Crook, D.W., Gorbach, S.L., Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin. Infect. Dis., S154-61, 2012.
12. Cotillard, A., Kennedy, S.P., Kong, L.C., Prifti, E., Pons, N., Le Chatelier, E., Almeida, M., Quinquis, B., Levenez, F., Galleron, N., Gougis, S., Rizkalla, S., Batto, J.M., Renault, P., Dore, J., Zucker, J.D., Clement, K., Ehrlich, S.D., Dietary intervention impact on gut microbial gene richness. Nature 7464 (2013), 585–588.
13. Dethlefsen, L., Huse, S., Sogin, M.L., Relman, D.A., The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol., 11, 2008, e280.
14. Duncan, S.H., Lobley, G.E., Holtrop, G., Ince, J., Johnstone, A.M., Louis, P., Flint, H.J., Human colonic microbiota associated with diet, obesity and weight loss. Int. J. Obes. 11 (2008), 1720–1724.
15. Faith, J.J., Guruge, J.L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A.L., Clemente, J.C., Knight, R., Heath, A.C., Leibel, R.L., Rosenbaum, M., Gordon, J.I., The long-term stability of the human gut microbiota. Science, 6141, 2013, 1237439.
16. Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder, M.J., Valles-Colomer, M., Vandeputte, D., Tito, R.Y., Chaffron, S., Rymenans, L., Verspecht, C., de Sutter, L., Lima-Mendez, G., D'Hoe, K., Jonckheere, K., Homola, D., Garcia, R., Tigchelaar, E.F., Eeckhaudt, L., Fu, J., Henckaerts, L., Zhernakova, A., Wijmenga, C., Raes, J., Population-level analysis of gut microbiome variation. Science 6285 (2016), 560–564.
17. Federal Drug Administration (FDA), Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM361393.pdf, 2013.
18. Fernandes, J., Su, W., Rahat-Rozenbloom, S., Wolever, T.M., Comelli, E.M., Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr. Diabetes, 2014 (e121-e121).
19. Ferrer, M., Ruiz, A., Lanza, F., Haange, S.B., Oberbach, A., Till, H., Bargiela, R., Campoy, C., Segura, M.T., Richter, M., von Bergen, M., Seifert, J., Suarez, A., Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environ. Microbiol. 1 (2013), 211–226.
20. Fischer, M., Kao, D., Mehta, S.R., Martin, T., Dimitry, J., Keshteli, A.H., Cook, G.K., Phelps, E., Sipe, B.W., Xu, H., Kelly, C.R., Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am. J. Gastroenterol. 7 (2016), 1024–1031.
21. Folke, C., Carpenter, S., Walker, B., Scheffer, M., Elmqvist, T., Gunderson, L., Holling, C.S., Regime shifts, resilience, and biodiversity in ecosystem management. Annu. Rev. Ecol. Evol. Syst. 1 (2004), 557–581.
22. Fuentes, S., van Nood, E., Tims, S., Heikamp-de Jong, I., ter Braak, C.J., Keller, J.J., Zoetendal, E.G., de Vos, W.M., Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection. ISME J. 8 (2014), 1621–1633.
23. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N.N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., Clarke, J.M., Topping, D.L., Tomita, M., Hori, S., Ohara, O., Morita, T., Koseki, H., Kikuchi, J., Honda, K., Hase, K., Ohno, H., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 7480 (2013), 446–450.
24. Gebhart, D., Lok, S., Clare, S., Tomas, M., Stares, M., Scholl, D., Donskey, C.J., Lawley, T.D., Govoni, G.R., A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity. MBio, 2, 2015.
25. Gill, S.R., Pop, M., Deboy, R.T., Eckburg, P.B., Turnbaugh, P.J., Samuel, B.S., Gordon, J.I., Relman, D.A., Fraser-Liggett, C.M., Nelson, K.E., Metagenomic analysis of the human distal gut microbiome. Science 5778 (2006), 1355–1359.
26. Girotra, M., Garg, S., Anand, R., Song, Y., Dutta, S.K., Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly: long-term outcomes and microbiota changes. Dig. Dis. Sci. 10 (2016), 3007–3015.
27. Hamilton, M.J., Weingarden, A.R., Unno, T., Khoruts, A., Sadowsky, M.J., High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2 (2013), 125–135.
28. Health Canada, Guidance document: fecal microbiota therapy used in the treatment of Clostridium difficile infection not responsive to conventional therapies. http://www.hc-sc.gc.ca/dhp-mps/consultation/biolog/fecal_microbiota-bacterio_fecale-eng.php, 2015.
29. Health Quality Ontario (HQO), Fecal microbiota therapy for Clostridium difficile infection: OHTAC recommendation. http://www.hqontario.ca/evidence-to-improve-care/recommendations-and-reports/OHTAC/fecal-microbiota-therapy, 2016.
30. Hecht, G.A., Blaser, M.J., Gordon, J., Kaplan, L.M., Knight, R., Laine, L., Peek, R., Sanders, M.E., Sartor, B., Wu, G.D., Yang, V.W., What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat Clostridium difficile infection?. Clin. Gastroenterol. Hepatol. 2 (2014), 289–291.
31. Hell, M., Bernhofer, C., Stalzer, P., Kern, J.M., Claassen, E., Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Benefic. Microbes 1 (2013), 39–51.
32. Hemmerling, A., Harrison, W., Schroeder, A., Park, J., Korn, A., Shiboski, S., Foster-Rosales, A., Cohen, C.R., Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex. Transm. Dis. 12 (2010), 745–750.
33. Hirsch, B.E., Saraiya, N., Poeth, K., Schwartz, R.M., Epstein, M.E., Honig, G., Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect. Dis., 191-191, 2015.
34. Human Microbiome Project (HMP) Consortium, Structure, function and diversity of the healthy human microbiome. Nature 7402 (2012), 207–214.
35. Kazerouni, A., Burgess, J., Burns, L.J., Wein, L.M., Optimal screening and donor management in a public stool bank. Microbiome., 75, 2015.
36. Kelly, C.R., Khoruts, A., Staley, C., Sadowsky, M.J., Abd, M., Alani, M., Bakow, B., Curran, P., McKenney, J., Tisch, A., Reinert, S.E., Machan, J.T., Brandt, L.J., Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann. Intern. Med., 2016, 10.7326/M16-0271.
37. Khanna, S., Pardi, D.S., Kelly, C.R., Kraft, C.S., Dhere, T., Henn, M.R., Lombardo, M.J., Vulic, M., Ohsumi, T., Winkler, J., Pindar, C., McGovern, B.H., Pomerantz, R.J., Aunins, J.G., Cook, D.N., Hohmann, E.L., A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2 (2016), 173–181.
38. Khoruts, A., Dicksved, J., Jansson, J.K., Sadowsky, M.J., Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 5 (2010), 354–360.
39. Khoruts, A., Rank, K.M., Newman, K.M., Viskocil, K., Vaughn, B.P., Hamilton, M.J., Sadowsky, M.J., Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol H. 14 (2016), 1433–1438.
40. Kump, P.K., Krause, R., Allerberger, F., Hogenauer, C., Faecal microbiota transplantation—the Austrian approach. Clin. Microbiol. Infect. 11 (2014), 1106–1111.
41. L'Agence nationale de sécurité du médicament et des produits de santé (ANSM), La transplantation de microbiote fecal et son encadrement dans les essais cliniques. http://ansm.sante.fr/var/ansm_site/storage/original/application/5e5e01018303790194275ded0e02353c.pdf, 2014.
42. Lapointe-Shaw, L., Tran, K.L., Coyte, P.C., Hancock-Howard, R.L., Powis, J., Poutanen, S.M., Hota, S., Cost-effectiveness analysis of six strategies to treat recurrent Clostridium difficile infection. PLoS One, 2, 2016, e0149521.
43. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.M., Kennedy, S., Leonard, P., Li, J., Burgdorf, K., Grarup, N., Jorgensen, T., Brandslund, I., Nielsen, H.B., Juncker, A.S., Bertalan, M., Levenez, F., Pons, N., Rasmussen, S., Sunagawa, S., Tap, J., Tims, S., Zoetendal, E.G., Brunak, S., Clement, K., Dore, J., Kleerebezem, M., Kristiansen, K., Renault, P., Sicheritz-Ponten, T., de Vos, W.M., Zucker, J.D., Raes, J., Hansen, T., Bork, P., Wang, J., Ehrlich, S.D., Pedersen, O., Richness of human gut microbiome correlates with metabolic markers. Nature 7464 (2013), 541–546.
44. Lepage, P., Hasler, R., Spehlmann, M.E., Rehman, A., Zvirbliene, A., Begun, A., Ott, S., Kupcinskas, L., Dore, J., Raedler, A., Schreiber, S., Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology 1 (2011), 227–236.
45. Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I., Microbial ecology: human gut microbes associated with obesity. Nature 7122 (2006), 1022–1023.
46. Li, S.S., Zhu, A., Benes, V., Costea, P.I., Hercog, R., Hildebrand, F., Huerta-Cepas, J., Nieuwdorp, M., Salojarvi, J., Voigt, A.Y., Zeller, G., Sunagawa, S., de Vos, W.M., Bork, P., Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 6285 (2016), 586–589.
47. Lin, H.V., Frassetto, A., Kowalik, E.J. Jr., Nawrocki, A.R., Lu, M.M., Kosinski, J.R., Hubert, J.A., Szeto, D., Yao, X., Forrest, G., Marsh, D.J., Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One, 4, 2012, e35240.
48. Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K., Knight, R., Diversity, stability and resilience of the human gut microbiota. Nature 7415 (2012), 220–230.
49. Marchesi, J.R., Ravel, J., The vocabulary of microbiome research: a proposal. Microbiome. 1 (2015), 1–3.
50. Marchesi, J.R., Adams, D.H., Fava, F., Hermes, G.D.a., Hirschfield, G.M., Hold, G., Quraishi, M.N., Kinross, J., Smidt, H., Tuohy, K.M., Thomas, L.V., Zoetendal, E.G., Hart, A., The gut microbiota and host health: a new clinical frontier. Gut, 2015, 1–10.
51. Merlo, G., Graves, N., Brain, D., Connelly, L., Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia. J. Gastroenterol. Hepatol., 2016.
52. Michail, S., Durbin, M., Turner, D., Griffiths, A.M., Mack, D.R., Hyams, J., Leleiko, N., Kenche, H., Stolfi, A., Wine, E., Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm. Bowel Dis. 10 (2012), 1799–1808.
53. Moayyedi, P., Surette, M.G., Kim, P.T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J.K., Kassam, Z., Reinisch, W., Lee, C.H., Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 1 (2015), 102–109 (e6).
54. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W., Kaplan, G.G., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 1 (2012), 46–54, e42 (quiz e30).
55. Motta, J.P., Magne, L., Descamps, D., Rolland, C., Squarzoni-Dale, C., Rousset, P., Martin, L., Cenac, N., Balloy, V., Huerre, M., Frohlich, L.F., Jenne, D., Wartelle, J., Belaaouaj, A., Mas, E., Vinel, J.P., Alric, L., Chignard, M., Vergnolle, N., Sallenave, J.M., Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 4 (2011), 1272–1282.
56. Ng, K.M., Ferreyra, J.A., Higginbottom, S.K., Lynch, J.B., Kashyap, P.C., Gopinath, S., Naidu, N., Choudhury, B., Weimer, B.C., Monack, D.M., Sonnenburg, J.L., Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 7469 (2013), 96–99.
57. Perez-Cobas, A.E., Artacho, A., Knecht, H., Ferrus, M.L., Friedrichs, A., Ott, S.J., Moya, A., Latorre, A., Gosalbes, M.J., Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One, 11, 2013, e80201.
58. Perez-Cobas, A.E., Gosalbes, M.J., Friedrichs, A., Knecht, H., Artacho, A., Eismann, K., Otto, W., Rojo, D., Bargiela, R., von Bergen, M., Neulinger, S.C., Daumer, C., Heinsen, F.A., Latorre, A., Barbas, C., Seifert, J., dos Santos, V.M., Ott, S.J., Ferrer, M., Moya, A., Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 11 (2013), 1591–1601.
59. Petrof, E.O., Khoruts, A., From stool transplants to next-generation microbiota therapeutics. Gastroenterology 6 (2014), 1573–1582.
60. Petrof, E.O., Gloor, G.B., Vanner, S.J., Weese, S.J., Carter, D., Daigneault, M.C., Brown, E.M., Schroeter, K., Allen-Vercoe, E., Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome., 1, 2013, 3.
61. Png, C.W., Linden, S.K., Gilshenan, K.S., E.G, Z., Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 11 (2010), 2420–2428.
62. Pullan, R.D., Thomas, G.A., Rhodes, M., Newcombe, R.G., Williams, G.T., Allen, A., Rhodes, J., Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 3 (1994), 353–359.
63. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., Mende, D.R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, B., Liang, H., Zheng, H., Xie, Y., Tap, J., Lepage, P., Bertalan, M., Batto, J.M., Hansen, T., Le Paslier, D., Linneberg, A., Nielsen, H.B., Pelletier, E., Renault, P., Sicheritz-Ponten, T., Turner, K., Zhu, H., Yu, C., Li, S., Jian, M., Zhou, Y., Li, Y., Zhang, X., Li, S., Qin, N., Yang, H., Wang, J., Brunak, S., Doré, J., Guarner, F., Kristiansen, K., Pedersen, O., Parkhill, J., Weissenbach, J., Bork, P., Ehrlich, S.D., Wang, J., A human gut microbial gene catalog established by metagenomic sequencing. Nature 7285 (2010), 59–65.
64. Rajilic-Stojanovic, M., Shanahan, F., Guarner, F., de Vos, W.M., Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm. Bowel Dis. 3 (2013), 481–488.
65. Rampelli, S., Schnorr, S.L., Consolandi, C., Turroni, S., Severgnini, M., Peano, C., Brigidi, P., Crittenden, A.N., Henry, A.G., Candela, M., Metagenome sequencing of the Hadza hunter-gatherer gut microbiota. Curr. Biol. 13 (2015), 1682–1693.
66. Ratner, M., Microbial cocktails join fecal transplants in IBD treatment trials. Nat. Biotechnol. 8 (2015), 787–788.
67. Rea, M.C., O'Sullivan, O., Shanahan, F., O'Toole, P.W., Stanton, C., Ross, R.P., Hill, C., Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J. Clin. Microbiol. 3 (2012), 867–875.
68. Relman, D.A., The human microbiome: ecosystem resilience and health. Nutr. Rev., S2-9, 2012.
69. Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., Griffin, N.W., Lombard, V., Henrissat, B., Bain, J.R., Muehlbauer, M.J., Ilkayeva, O., Semenkovich, C.F., Funai, K., Hayashi, D.K., Lyle, B.J., Martini, M.C., Ursell, L.K., Clemente, J.C., van Treuren, W., Walters, W.A., Knight, R., Newgard, C.B., Heath, A.C., Gordon, J.I., Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 6150, 2013, 1241214.
70. Rossen, N.G., Fuentes, S., van der Spek, M.J., Tijssen, J.G., Hartman, J.H., Duflou, A., Lowenberg, M., van den Brink, G.R., Mathus-Vliegen, E.M., de Vos, W.M., Zoetendal, E.G., D'Haens, G.R., Ponsioen, C.Y., Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 1 (2015), 110–118 (e4).
71. Scholl, D., Cooley, M., Williams, S.R., Gebhart, D., Martin, D., Bates, A., Mandrell, R., An engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the food-borne pathogen Escherichia coli O157:H7. Antimicrob. Agents Chemother. 7 (2009), 3074–3080.
72. Scholl, D., Gebhart, D., Williams, S.R., Bates, A., Mandrell, R., Genome sequence of E. coli O104:H4 leads to rapid development of a targeted antimicrobial agent against this emerging pathogen. PLoS One, 3, 2012, e33637.
73. Schubert, A.M., Rogers, M.A., Ring, C., Mogle, J., Petrosino, J.P., Young, V.B., Aronoff, D.M., Schloss, P.D., Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio 3 (2014), e01021–01014.
74. Schwiertz, A., Taras, D., Schafer, K., Beijer, S., Bos, N.A., Donus, C., Hardt, P.D., Microbiota and SCFA in lean and overweight healthy subjects. Obesity 1 (2010), 190–195.
75. Seekatz, A.M., Aas, J., Gessert, C.E., Rubin, T.A., Saman, D.M., Bakken, J.S., Young, V.B., Recovery of the gut microbiome following fecal microbiota transplantation. MBio, 3, 2014, e00893-14.
76. Seki, H., Shiohara, M., Matsumura, T., Miyagawa, N., Tanaka, M., Komiyama, A., Kurata, S., Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr. Int. 1 (2003), 86–90.
77. Seres Therapeutics Inc., Seres Therapeutics announces interim results from SER-109 phase 2 ECOSPOR Study in multiply recurrent Clostridium difficile infection. http://www.businesswire.com/news/home/20160729005385/en, 2016.
78. Shahinas, D., Silverman, M., Sittler, T., Chiu, C., Kim, P., Allen-Vercoe, E., Weese, S., Wong, A., Low, D.E., Pillai, D.R., Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio, 5, 2012.
79. Stapleton, A.E., Au-Yeung, M., Hooton, T.M., Fredricks, D.N., Roberts, P.L., Czaja, C.A., Yarova-Yarovaya, Y., Fiedler, T., Cox, M., Stamm, W.E., Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 10 (2011), 1212–1217.
80. Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., McFarland, L.V., Mellow, M., Zuckerbraun, B.S., Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 4 (2013), 478–498 (quiz 499).
81. Teixeira, T.F., Grzeskowiak, L., Franceschini, S.C., Bressan, J., Ferreira, C.L., Peluzio, M.C., Higher level of faecal SCFA in women correlates with metabolic syndrome risk factors. Br. J. Nutr. 5 (2013), 914–919.
82. The Gastroenterological Society of Australia (GESA), Position statement of faecal microbiota transplant (FMT). http://www.gesa.org.au/news.asp?id=541, 2015.
83. The Infectious Diseases Society of America (IDSA), Fecal microbiota transplantation: incestigational new drug protocol. http://www.idsociety.org/FMT, 2016.
84. The National Institute for Health and Care Excellence (NICE), Faecal microbiota transplant for recurrent Clostridium difficile infection. http://www.nice.org.uk/guidance/ipg485, 2014.
85. Theriot, C.M., Koenigsknecht, M.J., Carlson, P.E. Jr., Hatton, G.E., Nelson, A.M., Li, B., Huffnagle, G.B., Z Li, J., Young, V.B., Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun., 2014, 3114.
86. Theriot, C.M., Bowman, A.A., Young, V.B., Antibiotic-induced alterations of the gut microbiota alter secondary bile acid production and allow for Clostridium difficile spore germination and outgrowth in the large intestine. mSphere, 1, 2016.
87. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 7122 (2006), 1027–1131.
88. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, M.L., Jones, W.J., Roe, B.A., Affourtit, J.P., Egholm, M., Henrissat, B., Heath, A.C., Knight, R., Gordon, J.I., A core gut microbiome in obese and lean twins. Nature 7228 (2009), 480–484.
89. Tvede, M., Rask-Madsen, J., Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 8648 (1989), 1156–1160.
90. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E.G., de Vos, W.M., Visser, C.E., Kuijper, E.J., Bartelsman, J.F., Tijssen, J.G., Speelman, P., Dijkgraaf, M.G., Keller, J.J., Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 5 (2013), 407–415.
91. Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., van Huysse, J., Demetter, P., Steidler, L., Remaut, E., Cuvelier, C., Rottiers, P., Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 1 (2010), 49–56.
92. Villanueva-Millan, M.J., Perez-Matute, P., Oteo, J.A., Gut microbiota: a key player in health and disease. A review focused on obesity. J. Physiol. Biochem. 3 (2015), 509–525.
93. Vipperla, K., O'Keefe, S.J., Diet, microbiota, and dysbiosis: a ‘recipe’ for colorectal cancer. Food Funct. 4 (2016), 1731–1740.
94. Vrieze, A., Van Nood, E., Holleman, F., Salojarvi, J., Kootte, R.S., Bartelsman, J.F., Dallinga-Thie, G.M., Ackermans, M.T., Serlie, M.J., Oozeer, R., Derrien, M., Druesne, A., van Hylckama Vlieg, J.E., Bloks, V.W., Groen, A.K., Heilig, H.G., Zoetendal, E.G., Stroes, E.S., de Vos, W.M., Hoekstra, J.B., Nieuwdorp, M., Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 4 (2012), 913–916 (e7).
95. Vyas, D., Aekka, A., Vyas, A., Fecal transplant policy and legislation. World J. Gastroenterol. 1 (2015), 6–11.
96. Walker, A.W., Sanderson, J.D., Churcher, C., Parkes, G.C., Hudspith, B.N., Rayment, N., Brostoff, J., Parkhill, J., Dougan, G., Petrovska, L., High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol., 7-7, 2011.
97. Wang, Q., Euler, C.W., Delaune, A., Fischetti, V.A., Using a novel lysin to help control Clostridium difficile infections. Antimicrob Agents Ch. 12 (2015), 7447–7457.
98. Weingarden, A.R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V.M., Sadowsky, M.J., Khoruts, A., Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Phys. Gastrointest. Liver 4 (2014), G310–G319.
99. Weingarden, A., Gonzalez, A., Vazquez-Baeza, Y., Weiss, S., Humphry, G., Berg-Lyons, D., Knights, D., Unno, T., Bobr, A., Kang, J., Khoruts, A., Knight, R., Sadowsky, M.J., Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome., 10, 2015.
100. Yasueda, A., Mizushima, T., Nezu, R., Sumi, R., Tanaka, M., Nishimura, J., Kai, Y., Hirota, M., Osawa, H., Nakajima, K., Mori, M., Ito, T., The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. Surg. Today 8 (2016), 939–949.
101. Youngster, I., Sauk, J., Pindar, C., Wilson, R.G., Kaplan, J.L., Smith, M.B., Alm, E.J., Gevers, D., Russell, G.H., Hohmann, E.L., Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin. Infect. Dis. 11 (2014), 1515–1522.
102. Youngster, I., Mahabamunuge, J., Systrom, H.K., Sauk, J., Khalili, H., Levin, J., Kaplan, J.L., Hohmann, E.L., Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med., 1, 2016, 134.
103. Zhernakova, A., Kurilshikov, A., Bonder, M.J., Tigchelaar, E.F., Schirmer, M., Vatanen, T., Mujagic, Z., Vila, A.V., Falony, G., Vieira-Silva, S., Wang, J., Imhann, F., Brandsma, E., Jankipersadsing, S.A., Joossens, M., Cenit, M.C., Deelen, P., Swertz, M.A., Weersma, R.K., Feskens, E.J., Netea, M.G., Gevers, D., Jonkers, D., Franke, L., Aulchenko, Y.S., Huttenhower, C., Raes, J., Hofker, M.H., Xavier, R.J., Wijmenga, C., Fu, J., Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 6285 (2016), 565–569.